Addison's Syndrome Over the forecast period, the market is predicted to increase considerably. The market is expected to be worth USD 587.45 million in 2030, and it is expected to increase at a CAGR of 10.70% over the forecast period. Addison's disease is a condition in which the body generates insufficient levels of certain hormones made by the adrenal glands. The adrenal glands generate too little cortisol and typically insufficient quantities of aldosterone in people with Addison's disease.
Adrenal insufficiency is another name for it. Addison's disease may afflict people of all ages and impact both men and women. The market is predicted to rise due to reasons such as the rising prevalence of Addison's disease, increased awareness of the condition, and rising healthcare spending. Lack of knowledge and difficulty to detect the condition in its early stages, on the other hand, may limit market growth throughout the projection period.Segmentation
The market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, and other end users.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Addison’s disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
Regional Market Summary
Global Addison’s Disease Market Share (%), by Region, 2017
Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports
Geographically, the Americas is anticipated to dominate the global Addison's disease market owing to a well-developed healthcare sector and the rising prevalence of the disease. According to a report published by the Centers Medicare and Medicaid Services in April 2018, National Healthcare Expenditure grew by 4.3% to USD 3.3 trillion in 2016 from the previous year.
Europe is expected to hold the second largest position in the global market. The market growth in this region is attributed to the increasing number of Addison’s disease cases and the developed healthcare infrastructure. According to the World Health Organization, Germany spent USD 5182 per capita on healthcare.
The Addison’s disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the increasing prevalence of Addison’s disease and growing awareness of the same. According to the World Bank Group, India spent 3.89% of its GDP on health in 2015.
The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.Recent Development
Lupin Ltd (Lupin) is a pharmaceutical company that produces and markets generic and branded pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Cardiovascular, diabetes etc are all part of the company's product range. Oral, ophthalmic, dermatological, and inhalation product research are key priorities for the organization. The company's operations are reported under a single segment, Pharmaceuticals. Formulations, active pharmaceutical ingredients (APIs), generic formulations, and biotechnology products are all part of Lupin's business.
In August 2015, Amgen, a biotechnology corporation located in the United States, launched its significantly enlarged production plant in Dun Laoghaire, Ireland. The $300 million expansion expanded manufacturing facilities to the existing factory, enhancing its capabilities and positioning it as a major hub for Amgen's global operations. The move was part of Amgen's long-term plan to manufacture all of its pharmaceuticals at the Dun Laoghaire facility, ensuring a steady supply of Amgen's medicines for severely sick patients across the world.
Global Addison’s Disease Market, by Diagnosis
Global Addison’s Disease Market, by Treatment
Global Addison’s Disease Market, by End User
Global Addison’s Disease Market, by Region
Global Addison’s Disease Market, by Key Players
| Report Attribute/Metric | Details |
| Market Size | USD 587.45 million |
| CAGR | 2020-2030:10.70% |
| Base Year | 2020 |
| Forecast Period | 2030 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Diagnosis, Treatment And End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Pfizer Inc., Boehringer Ingelheim International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline plc, Merck KGaA, Lupin Pharmaceuticals, Inc., Abbott, Amgen Limited & Amgen Ireland Limited, Bayer AG, Biogen, Eli Lilly and Company, Novartis AG, Diurnal, Switzer Life science Pvt. Ltd |
| Key Market Opportunities | R&D Activities |
| Key Market Drivers | · Growing prevalence of Addison’s disease · Increasing awareness of the disease · Rising healthcare expenditure |
Addison’s Disease Market Highlights:
Frequently Asked Questions (FAQ) :
The Addison’s disease market is projected to grow at a 10.70% CAGR between 2020-2030.
North America is projected to command the largest share in the Addison’s disease market.
Oral corticosteroids segment will dominate the Addison’s disease market.
Rising healthcare expenditure and growing awareness about the disease is boosting market growth.
Inability to diagnose Addison’s disease may limit market growth.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
